Profil
Daniel Deardorf is currently the Chief Executive Officer & Director at Glycologix, Inc. He previously worked as the Senior Vice President-Commercial at Flexion Therapeutics, Inc.
Postes actifs de Daniel Deardorf
| Sociétés | Poste | Début |
|---|---|---|
Glycologix, Inc.
 Glycologix, Inc. BiotechnologyHealth Technology Glycologix, Inc. is an American biotechnology company that develops delivered biopolymers for the protection and repair of soft tissues. Glycologix was founded by Thomas Jozefiak and George Adaniya, and the CEO is Dan Deardorf. | Directeur Général | 01/01/2021 |
Anciens postes connus de Daniel Deardorf
| Sociétés | Poste | Fin |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Glycologix, Inc.
Glycologix, Inc. BiotechnologyHealth Technology Glycologix, Inc. is an American biotechnology company that develops delivered biopolymers for the protection and repair of soft tissues. Glycologix was founded by Thomas Jozefiak and George Adaniya, and the CEO is Dan Deardorf. | Health Technology |
